Foscarbidopa

Summary

Foscarbidopa (CHEMBL4802240) is an approved small-molecule prodrug; indicated across 1 condition including parkinson disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 306.21 Da · C10H15N2O7P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802240
Name	Foscarbidopa
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	121288738
ChEBI	CHEBI:192511
Molecular formula	C10H15N2O7P
Molecular weight	306.21
InChIKey	PQUZXFMHVSMUNG-JTQLQIEISA-N

SMILES: C[C@](CC1=CC(=C(C=C1)OP(=O)(O)O)O)(C(=O)O)NN

IUPAC name: (2S)-2-hydrazinyl-3-(3-hydroxy-4-phosphonooxyphenyl)-2-methylpropanoic acid

ChEBI definition: An L-tyrosine derivative that is carbidopa in which the hydroxy group at position 4’ is replaced by a phosphonooxy group. It is a water-soluble prodrug of carbidopa which is used for the treatment of Parkinson’s disease.

Pharmacological roles (ChEBI): prodrug, antiparkinson drug.

Also known as: ABBV-951 Carbidopa, Carbidopa 4’-monophosphate, Foscarbidopa, Foscarbidopa component of abbv-951, Foscarbidopa component of vyalev, FOSCARBIDOPA

Patent coverage: 21 distinct patent families (62 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 45 (73%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Parkinson disease	1	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).